Introduction
============

The impact of synbiotics on enteral feeding tolerance and immune function has been studied. We designed a protocol monitoring impact of synbiotics on these variables in long-term ICU patients.

Patients and methods
====================

Patients estimated on D1 (D0 = admission) to stay in the ICU \>3 days were randomized (according to age, sex, SOFA score and diagnosis group) to postpyloric placebo (tea) or treatment (Synbiotic) groups. Monocyte function was monitored on D1 and then at 5-day intervals; enteral nutrition (EN) was given according to the standard ICU protocol.

Preliminary analysis of early development (D1--D5--D10) of CD14^+^HLADR^+^expression and tolerance of enteral feeding is reported. Data are presented as the median (Q25; Q75). Kruskal-Wallis ANOVA and Wilcoxon tests were used when appropriate, *P*\< 0.05 considered significant.

Results
=======

Twelve patients (10 male, two female; age 54 \[39; 63\] years) were randomized and 11 were eligible for analysis (Synbiotic *n*= 6, placebo *n*= 5). Ten patients survived the ICU stay (S), and one did not (NS). The APACHE II score on admission was 22 (21; 26.5). The course of CD14^+^HLADR^+^did not differ in the Synbiotic/placebo groups (Table [1](#T1){ref-type="table"}). In two placebo and no Synbiotic patients a significant drop of 15% was measured. The amount of EN (10 days) is higher in the Synbiotic than the placebo group (6930 ml \[6490; 7292\] vs 5010 ml \[4747; 5237\], *P*\< 0.05), as was the frequency of stool (9 \[4; 14\] vs 1 \[0; 4\], *P*= 0.13).

                       CD14^+^HLADR^+^                 
  -------------------- ----------------- ------------- -------------
  Synbiotic (*n*= 6)   49 (33; 59)       60 (56; 72)   71 (65; 79)
  Placebo (*n*= 5)     54 (33; 66)       57 (44; 57)   53 (51; 57)

Conclusion
==========

Preliminary data do not show a major impact of synbiotics on monocyte function. Tolerance of EN seems to be better in the synbiotics group.
